BERLIN, July 13, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that the U.S. Food and Drug Administration (FDA) accepted the Investigative New Drug (IND) application submitted by Jerini’s wholly-owned subsidiary, Jerini Ophthalmic, Inc., for JSM 6427 in the treatment of age-related macular degeneration (AMD). IND acceptance will allow Jerini Ophthalmic to begin Phase I testing of JSM 6427, currently planned for October 2007. JSM 6427 is a small molecule in development to prevent the progression of dry AMD to wet AMD, an unmet medical need affecting 600,000 patients in the United States. A product of Jerini’s Peptides-to-Drugs (P2D) technology platform, JSM 6427 is being developed by Jerini Ophthalmic, which specializes in ophthalmologic disease indications.
